News & Updates

The European Medicines Agency has begun a formal review of Tavneos (avacopan) after emerging information raised questions about the integrity of key clinical trial data supporting its EU authorisation, with potential implications for adults living with rare autoimmune vasculitis.
On 24 February, in Brussels and online, EURORDIS will bring the rare disease community together for its fifteenth Black Pearl Awards ceremony, held in the lead‑up to Rare Disease Day.
Greater efforts are needed to invest in infrastructure, foster inclusive study designs and align research agendas.
A draft ICH E22 guideline on patient preference studies is now open for public comment via the European Medicines Agency until 12 April 2026.
Following the 11 December 2025 political agreement, EU institutions are moving towards formal adoption of a new Directive and Regulation that will reshape how medicines—including orphan and paediatric medicines—are developed, authorised and supplied across the European Union.
Experts from Europe’s major health data initiatives met virtually to discuss how the European Genomic Data Infrastructure is supporting partner projects, and why sustained collaboration is central to Europe’s wider health and research data ambitions.
Rare disease researchers, clinicians, patient advocates and data experts are invited to help shape four new IRDiRC activities linked to the new IRDiRC Roadmap, with applications closing on 20 February 2026.
The RealiseD project launched a new multi-stakeholder survey that invites the rare disease community to share insights and help improve clinical trial enrolment
Feb
24
Tuesday,
06:30 pm-11:00 pm
hybrid

Annual awards celebrating outstanding achievements by people living with a rare disease and those making a difference across the rare disease community (patient advocacy, policy, science, care, industry and beyond).

Feb
25
Wednesday,
01:00 pm-02:00 pm
online

A short webinar to launch a new, friendly guide to Equality, Diversity and Inclusion (EDI) in Public and Patient Involvement (PPI).

Mar
02
Monday,
All day
online

The proposal for the EU pharmaceutical legislation introduces the concepts of platform technologies and platform marketing authorisation. The European Medicines Agency organises a webinar bringing together regulators and medicine developers to […]

Mar
02
- 01
Jul
Monday,
8:00 am - 5:00 pm
hybrid

The training responds to the growing need for patient advocates to understand data management, ethical considerations and the role of AI in rare disease research.

Mar
05
- 06
Mar
Thursday,
All day
onsite
Cyprus Institute of Neurology and Genetics, Nicosia

The two-day event will focus on translating research and policy initiatives into tangible benefits for Rare Disease patients through better prevention, diagnosis, and treatment.

May
12
- 13
May
Tuesday,
All day
onsite

Join the leading international drug repurposing conference to explore the future of patient-centric medicines repurposing!

Jun
03
- 04
Jun
Wednesday,
All day
hybrid

The next ECRD will take place on 3–4 June 2026 in Prague under the title “Rare Diseases in a Changing & Competitive Europe: Shaping policies to address the unmet needs of people living with rare diseases”.

Jun
09
- 22
Jun
Tuesday,
All day
onsite

More than 280 speakers from industry, regulators, patient organisations, investors and healthcare providers, and aims to showcase new science, technologies and policies that can accelerate orphan drug development and improve access to therapies for people living with rare conditions.

When it comes to rare diseases, more than 70% have a genetic origin. To truly understand these conditions—and find ways to treat them—we need to start at the root: our DNA.
Significant health inequities pose challenges for those living with a rare disease
Published on 14 December, this WHO technical document maps global trends in registered clinical studies using human genomic technologies from 1990 to 2024, including patterns of inclusion and equity.
Open for consultation from 12 December to 12 April, this draft ICH guideline sets out how to design and submit robust patient preference studies to inform regulatory decision‑making across a medicine’s lifecycle.
Outside traditional drug development pathways, clinicians and scientists face the challenge of systematically evaluating whether individual patients with severe ultrarare diseases might be eligible for and potentially benefit from individualized mutation-specific RNA therapies.
Using Morocco as a case study, this paper shows how underrepresented countries contribute unique genetic insights to rare disease research and why their integration into initiatives like ERDREA is essential for both scientific progress and equity.
With over 300 million people affected by rare diseases, timely access to effective therapies is critical. Despite strong alignment in regulatory expectations, patients in many regions face years of delays highlighting the need for improved international coordination.
PROTRIDER is a method for detecting aberrant protein expression from mass spectrometry data that outperforms existing approaches and identifies enrichments of pathogenic variants, supporting its application in rare disease diagnostics and cancer proteomics.
Regulatory sandboxes have emerged as an innovative mechanism to facilitate the development and approval of new technologies, including pharmaceuticals. Their application in the context of rare disease therapies presents a promising avenue to accelerate the development, approval, and access to disease-modifying and life-saving therapies. Given the complexities of rare diseases and the regulatory hurdles faced by orphan medicinal products, regulatory sandboxes offer a structured yet flexible environment where new regulatory approaches can be tested and refined.
Complex regional pain syndrome (CRPS) is a rare, disabling pain disorder. Systematic reviews have identified a critical lack of high-quality clinical trial evidence to inform the management of CRPS. There is an urgent need to find solutions to the methodological challenges of undertaking clinical trials in CRPS. The aim of this project was to develop a methodological framework for optimising future clinical trials in CRPS (OptiMeth-CRPS).
First published on 29 September, this EMA reflection paper encourages early dialogue with regulators on how patient experience data can strengthen evidence packages in medicines development and marketing authorisation.

Victoria Hedley explains the role of National Mirror Groups in the rare disease research ecosystem

Victoria has spent the past 15 years contributing to the development of rare disease (RD) policies and policy‑related outputs, and is a founder and co‑lead of the Newcastle Centre for Rare Disease. Her current work includes leading activities within the European RD Research Alliance (ERDERA) to establish and mobilise National Mirror Groups for rare diseases; serving as co‑lead for the Coordinating Hub of the Rare Disease Research UK platform; and providing Newcastle University leadership for the Work Package on Impact, Regulation, and International Engagement within the LifeArc Centre for Acceleration of Rare Disease Trials.

In this video, Victoria Hedley explains the role of National Mirror Groups in the rare disease research ecosystem.

Shaping the future of rare disease research: insights from ERDERA

Launched in September 2024, ERDERA is already building strong momentum across the rare disease research landscape.

In this video, members of the ERDERA partnership reflect on what has been achieved so far, what the initiative represents for the wider rare disease research ecosystem, and the impact it is expected to have in the years ahead.

Hear insights from James Levine, Daria Julkowska, Bojana Mirosavljevic, and Milan Macek as they share their perspectives on collaboration, progress, and the future of rare disease research in Europe and beyond.

Watch the video!

How Clinical Research Networks are transforming rare disease research | CRNs conference highlights

The 2nd International Conference on Clinical Research Networks (CRNs) showcased the vital role of CRNs as structured collaborations that unite expert clinical sites, laboratories, patient organisations and other key stakeholders. In this video, hear directly from conference participants as they share insights on how Clinical Research Networks are accelerating prevention, diagnosis, observational studies and clinical trials for rare and groups of rare diseases. Discover how CRNs are helping to shape the future of rare disease research, innovation and patient care worldwide. The conference was organised by ERDERA, Rare Diseases International (RDI) and the International Rare Diseases Research Consortium (IRDiRC). Next edition: December 2027.

ERDERA’s Networking Support Scheme – Ethics Self Assessment Tutorial

Are you preparing a proposal for the Networking Support Scheme?

This tutorial walks you through how to accurately complete the Ethics Self-Assessment Table, adapted from the Horizon Europe template.

Completing Section 9 for any other ethical issues relevant to your proposal. Whether you’re new to the application process or just need a refresher, this step-by-step guide will help ensure you meet the ethical requirements of your submission. Don’t forget to like, share, and subscribe for more guidance on EU funding calls and application processes.

Together4RD x ERDERA: Launch of the Toolkit for Public-Private Partnerships in Rare Disease Research

The #Together4RD Toolkit is a new strategic resource to support effective, transparent, and impactful ERN-industry collaborations in #RareDisease research. Developed with input from both #ERN and industry, the Toolkit offers practical guidance, case studies, and tools to tackle legal, structural, and practical barriers to public-private partnerships.

Rare Disease Community | Tomasz Grybek

🗣 Throughout the week leading to Rare Disease Day 2025, we will be sharing insights from diverse voices highlighting key pathways to improving the lives of those affected. ️

Tomasz Grybek, carer, patient advocate, and Member Board of Directors of EURORDIS – a remarkable alliance of over 1,000 rare disease patient organisations from 74 countries – reminds us of the incredible strength and unity within the rare disease community.

Rare Disease Community | Dorica Dan

🗣 Throughout the week leading to Rare Disease Day 2025, we will be sharing insights from diverse voices highlighting key pathways to improving the lives of those affected. ️

In this video, Dorica Dan, rare disease carer and EURORDIS-Rare Diseases Europe Vice-Director, highlights the profound importance of early diagnosis for people living with a rare disease and their families – even when no treatment is available.

Rare Disease Community | Alexandre Méjat

🗣 Throughout the week leading to Rare Disease Day 2025, we will be sharing insights from diverse voices highlighting key pathways to improving the lives of those affected. ️

In this video, Alexandre Méjat, a rare disease patient, PhD scientist in the field of rare diseases, and EURORDIS Director, shares his invaluable insight on the vital role of data collection in achieving quicker diagnoses.

Our mission | Daria Julkowska, ERDERA Scientific Coordinator

For millions of people, rare diseases are more than just statistics—they are daily challenges, unanswered questions, and battles for better care. At ERDERA, our mission is simple but urgent: to improve the lives of over 30 million people living with rare diseases in Europe. In this video, Daria Julkoska, ERDERA’s Coordinator, explains the three essential ways how ERDERA plans to work towards a brighter future for people living with rare diseases.